Recently, the National Medical Products Administration accepted the drug registration application of Motomidate Hydrochloride Injection (Project Code: ET-26, Application Registration Category: Class 1 Chemical Drug; hereinafter referred to as "the new drug") by Jinzhou Aohong Pharmaceutical Co., Ltd., a subsidiary of Fosun Pharma (stock code: 600196.SH; 02196.HK). The proposed indication for this application is for anesthesia induction and short-term surgical anesthesia.
This new drug is a Class 1 new drug for intravenous general anesthesia and was included in the "Major New Drug Development" science and technology major project in 2014.According to the latest data from IQVIA CHPA1 , in 2024, sales of similar drugs (such as etomidate) used for anesthesia induction and short-term surgical anesthesia in mainland China (excluding Hong Kong, Macao and Taiwan) amounted to approximately RMB 4.238 billion.As a wholly-owned subsidiary of Fosun Pharma, Aohong Pharmaceutical has always regarded innovation as the core driving force for its sustainable development. Adhering to a patient-centered approach, it focuses on unmet clinical needs, continuously promotes the research and development of differentiated, high-tech innovative products, and constantly enriches and enhances the value of its product pipeline. In the future, Aohong Pharmaceutical will continue to focus on investment in innovative research and development, committed to improving the accessibility of high-quality medicines, and enabling innovative achievements to benefit a wider range of patients.

https://bydrug.pharmcube.com/news/detail/d110591adabaee4ee08c54979ff57155